TY - JOUR T1 - BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - 235 LP - 236 DO - 10.1136/sextrans-2022-055425 VL - 98 IS - 3 AU - Manik Kohli AU - Nicholas Medland AU - Helen Fifer AU - John Saunders Y1 - 2022/05/01 UR - http://sti.bmj.com/content/98/3/235.abstract N2 - In 2017, BASHH and Public Health England, now the UK Health Security Agency (UKHSA), published a position statement on the use of doxycycline as prophylaxis for STIs.1 It advised ‘extreme caution in the use of doxycycline [as post-exposure prophylaxis (PEP)]…[and] that the use of doxycycline PEP should be restricted to the research setting’. However, increasingly evidence suggests that individuals at higher risk of acquiring bacterial STIs are already using antibiotics to prevent acquisition, accessed through several routes.2–5 Clinicians are therefore likely to be seeing patients who are self-sourcing antibiotics as STI prophylaxis. For that reason, and to support a person-centred approach to care, the BASHH position statement has been updated. It now includes information about key studies to date and concerns around antimicrobial resistance (AMR) in sexually and non-sexually transmitted infections, as well as providing recommendations for clinicians for how to advise patients about STI prophylaxis. Importantly, it remains the case that doxycycline taken as PEP or pre-exposure prophylaxis (PrEP) for STIs is not endorsed by BASHH or UKHSA. This remains … ER -